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Background. Waist girth and BMI are commonly used as markers of cardiometabolic risk. Accumulating data however suggest
that sagittal abdominal diameter (SAD) or “abdominal height” may be a better marker of intra-abdominal adiposity and
cardiometabolic risk. We aimed to identify cutoﬀs for SAD using a cardiometabolic risk score. Design. A population-based cross-
sectional study. Methods. In 4032 subjects (1936 men and 2096 women) at age 60, diﬀerent anthropometric variables (SAD, BMI,
waist girth, and waist-to-hip ratio) were measured and cardiometabolic risk score calculated. ROC curves were used to assess
cutoﬀs. Results. Among men SAD showed the strongest correlations to the majority of the individual risk factors; whereas in
women SAD was equal to that of waist girth. In the whole sample, the area under the ROC curve was highest for SAD. The optimal
SAD cutoﬀ for an elevated cardiometabolic risk score in men was ∼22cm (95%CI; 21.6 to 22.8) and in women ∼20cm (95%CI;
19.4 to 20.8). These cutoﬀs were similar if the Framingham risk score was used. Conclusions.T h e s ec u t o ﬀs may be used in research
and screening to identify “metabolically obese” men who would beneﬁt from lifestyle and pharmacological interventions. These
results need to be veriﬁed in younger age groups.
1.Introduction
Anthropometric measures are widely used as simple markers
to identify subjects at risk of cardiovascular disease and
diabetes. A high BMI reﬂects generalized overweight and
obesity and is associated with cardiovascular morbidity and
mortality. Abdominal obesity, especially visceral obesity,
is however more hazardous than generalized obesity [1].
Abdominal fat distribution is commonly measured as waist
girth or waist/hip ratio, measures that have been shown to
predict cardiovascular disease independent of BMI [2, 3]. In
fact, a recent large meta-analysis suggests that BMI is not
a signiﬁcant predictor of cardiovascular mortality except in
patients with severe obesity [4].
More recently, “abdominal height” or sagittal abdominal
diameter (SAD) has shown to be strongly associated with
glucose intolerance [5], cardiovascular risk [5–9], and mor-
tality [10–13], independently of other anthropometric mea-
sures. SAD is also an excellent estimate of visceral fat [14–16]
implying that SAD might be a particularly good marker of
insulin resistance, which also has been demonstrated in men
[17]a n dw o m e n[ 18]. Despite these promising data, the role
of SAD has been overlooked whereas waist girth has received
more attention [5, 19–21]. We have previously reported that
SADwasabetterpredictorofcardiometabolicriskcompared
to waist girth and other conventional measures [7]. Now we
thus need cutoﬀs for SAD, data that needs to be derived from
a large population-based sample comparing SAD with other
measures of abdominal obesity. It is necessary to identify
cutoﬀs in order to use SAD either in research as a screening
tool or in the clinic to identify individuals with elevated
cardiometabolic risk.2 Journal of Obesity
Hence, the aim of this study was to identify optimal
cutoﬀs for SAD to be used in future prospective studies and
research. In a population-based sample of Swedish subjects
aged 60 we compared SAD with other more conventional
anthropometric measures.
2.MaterialandMethods
2.1. Subjects. In 1997 to 1999, every third man and woman
(n = 5460 in total, 2681 men and 2779 women) living in
Stockholm County, Sweden, born between 1937 and 1938,
was invited to participate in a health screening survey. Of
all invited, 4228 individuals agreed to participate (2036
men and 2192 women, 78% response rate), representing
the general population of subjects aged 60 [22]. In the
currentstudyweexcludedsubjectswithoutcompletedataon
all anthropometric, metabolic and cardiovascular variables,
resulting in 4032 subjects (1936 men, and 2096 women) that
comprise the current study population.
2.2. Clinical Investigation. All subjects underwent a physical
examination including anthropometry and blood biochem-
istry after an overnight fast [22]. Body weight was mea-
sured using an electronic scale to the nearest 0.1kg, with
the subjects wearing light clothing and no shoes. Height
was measured without shoes to nearest 0.5cm. BMI was
calculated as weight (kg) divided by height (m) squared.
SAD (anteroposterior) or “abdominal height” was measured
afteranormalexpirationtonearest0.1cminsupineposition
with straight legs on a ﬁrm examination table, without
clothes in the measurement area. At the level of iliac crest
(L4-5).SAD was measured using a ruler and water level.
SAD was the distance between the examination table up to
the horizontal level. Intraobserver variation (coeﬃcient of
variation) for SAD was 1.6%, and intrasubject variation was
2.7% [23]. Waist girth was measured according to the WHO
in underwear in standing position after normal expiration,
midway between the lower rib margin and the iliac crest and
hip girth was measured at symphysis trochanter level [24].
Systolic and diastolic blood pressures were measured
twice after 5 minutes rest in supine position, using a digital
blood pressure monitor (HEM 711, OMROM Health Care)
and the mean of the two values was calculated [22].
Venous blood was drawn from antecubital vein after
overnight fasting. All blood samples were analyzed online
during the study. Cholesterol and triglycerides in serum
were analyzed by enzymatic methods (Bayer diagnostics,
Tarrytown, USA) [25, 26]. HDL-cholesterol in serum
was measured enzymatically after isolation of LDL and
VLDL (Boehringer Mannheim GmbH, Germany) and LDL-
cholesterol was estimated using Friedewald’s method [27].
ApoB and apoA-I were determined by an immunoturbidi-
metric method [28]. Serum glucose was measured with an
enzymatic colorimetric test (Bayer Diagnostics, Tarrytown,
USA) [29]. Serum insulin levels were determined using the
ELISA technique (Boeringer Mannheim GmbH, Diagnos-
tica, Germany). Plasma ﬁbrinogen was measured with a
functional spectrophotometric test (Boehringer Mannheim,
Germany) [30]. γ-glutamyltransferase in serum was deter-
mined using an enzymatic colorimetric test (Bayer Diagnos-
tics, Tarrytown, USA).
2.3. Statistical Analyses. Variables that were skewed were
logarithmically transformed before statistical analysis. All
metabolic and anthropometric variables were normally
distributed after transformation. Pearson’s correlation coef-
ﬁcients were used to investigate the associations between
anthropometric and metabolic variables. An established
cardiometabolic risk score (reﬂecting metabolic aberrations
related to the metabolic syndrome) was calculated, and
comprised serum triglycerides, HDL-cholesterol, fasting
glucose, fasting insulin, and supine systolic and diastolic
blood pressures [7]. Each item was converted to quintiles.
For all items except HDL-cholesterol the 20% lowest values
were given the quintile value 1 and so on. HDL-cholesterol
was given quintile numbers in the reverse order, so that
the 20% with the lowest values were given the quintile
value 5, and so forth. The risk score was calculated as
the sum of quintiles over all items. The sum may span
from 6 to 30 and a value above the 80th percentile within
each sex was deﬁned as an elevated cardiometabolic risk
score [7]. In addition to the cardiometabolic risk score,
we also identiﬁed cutoﬀs by using the Framingham risk
score (http://www.nhlbi.nih.gov/guidelines/cholesterol/risk
tbl.htm). We deﬁned an elevated Framingham risk score
as the highest quintile per gender, thus we used a similar
deﬁnition as for the cardiometabolic risk score to facilitate
comparison. From the Framingham point scores, total
Framingham risk was estimated as a 10-year risk (%) of
having cardiovascular disease.
For each anthropometric measure, a Receiver Operating
Characteristic (ROC) curve was calculated for prediction of
an elevated cardiometabolic risk score, within each sex. The
c-statistic (area under the ROC curve) and an optimal cutoﬀ,
calculated from the Youden index [31] (the maximal sum
of sensitivity and speciﬁcity), are presented. The sensitivity
and speciﬁcity (with conﬁdence intervals) based on the
optimal cutoﬀ are also presented. Conﬁdence intervals for
the Cutoﬀs were assessed with the bootstrap normal approx-
imation method [32]. We used 10000 bootstrap samples.
Conﬁdence intervals for the c-statistic and signiﬁcance tests
for comparison of c-statistics from diﬀerent anthropometric
measures were calculated according to the method described
by DeLong et al. [33].
P<. 05 was regarded as statistically signiﬁcant. JMP
and SAS version 9 software packages were used for statistical
analyses (SAS Institute Inc., Cary, NC, USA).
3. Results
Themean(SD)cardiometabolicriskscorewas14(5)formen
and 10 (5) for women.
Baseline characteristics of subjects with data on all
variables are presented as quintiles for men and women,
respectively (Tables 1 and 2). All anthropometric measures
were signiﬁcantly correlated with all individual risk factorsJournal of Obesity 3
Table 1: Individual anthropometric measures and cardiometabolic risk factors divided into quintiles in men.
Quintile 1 Quintile 2 Quintile 3 Quintile 4 Quintile 5
SAD (cm) 18.1 ±2.11 8 .8 ±2.21 9 .4 ± 2.32 0 .5 ±2.62 2 .0 ±3.0
Waist (cm) 79.0 ±8.78 2 .5 ±9.08 5 .0 ±10.48 9 .8 ±10.99 5 .7 ± 12.4
Waist-to-hip ratio 0.8 ±0.05 0.81 ±0.05 0.82 ±0.05 0.85 ±0.06 0.88 ± 0.06
BMI 24.2 ±3.52 5 .3 ±3.62 6 .1 ± 4.07 .7 ±4.52 9 .8 ±5.0
Glucose (mmol/L)∗ 4.7 ±0.44 .9 ±0.55 .2 ±0.85 .5 ±1.36 .2 ± 2.3
Insulin (mU/L)∗ 6.1 ±4.07 .5 ±3.19 .4 ±5.21 0 .6 ±5.11 4 .5 ±7.9
Triglycerides (mmol/L)∗ 0.8 ±0.21 .0 ±0.41 .1 ±0.51 .4 ±0.61 .9 ± 0.9
LDL cholesterol (mmol/L)∗ 3.7 ±0.93 .8 ±0.93 .9 ±1.04 .0 ±0.94 .1 ± 1.0
HDL cholesterol (mmol/L)∗ 1.9 ±0.31 .7 ±0.41 .7 ±0.41 .5 ±0.41 .4 ± 0.3
ApoB/ApoA1 0.56 ± 0.10 .61 ±0.20 .66 ± 0.20 .71 ±0.20 .81 ±0.2
Systolic BP (mm Hg)∗ 114 ±11 124 ±15 136 ± 19 142 ±20 153 ±20
Diastolic BP (mm Hg)∗ 72 ±67 7 ±78 2 ± 98 5 ±98 9 ±9
Fibrinogen (g/L) 2.7 ±0.62 .9 ±0.73 .1 ±0.73 .2 ±0.83 .4 ± 0.8
γ-Glutamyltransferase (μkat/L) 0.39 ±0.70 .40 ±0.30 .48 ± 0.60 .7 ±0.90 .7 ± 1.0
Data are Mean ± SD. ∗Risk factors included in the cardiometabolic risk score.
Table 2: Individual anthropometric measures and cardiometabolic risk factors divided into quintiles in women.
Quintile 1 Quintile 2 Quintile 3 Quintile 4 Quintile 5
SAD (cm) 19.4 ±2.02 0 .4 ±2.02 1 .5 ±2.32 2 .1 ±2.42 3 .8 ± 2.7
Waist (cm) 90.0 ±8.39 4 .1 ±8.09 7 .9 ±8.3 100.3 ±8.0 106.0 ± 10.3
Waist-to-hip ratio 0.91 ± 0.05 0.93 ±0.05 0.96 ±0.05 0.97 ±0.05 0.99 ±0.05
BMI 24.3 ±2.62 5 .6 ±2.92 7 .0 ±3.22 7 .8 ±3.43 0 .0 ± 3.8
Glucose (mmol/L)∗ 5.0 ±0.75 .3 ±0.95 .7 ±1.46 .0 ±1.86 .9 ±2.5
Insulin (mU/L)∗ 6.4 ±3.57 .9 ±3.51 0 .2 ±4.91 2 .7 ±9.11 8 .1 ±10.3
Triglycerides (mmol/L)∗ 0.8 ±0.51 .1 ±0.61 .3 ±0.61 .7 ±0.92 .3 ±1.5
LDL cholesterol (mmol/L)∗ 3.6 ±0.83 .8 ±0.93 .8 ±0.93 .9 ±0.83 .9 ±0.9
HDL cholesterol (mmol/L)∗ 1.5 ±0.31 .4 ±0.31 .3 ±0.31 .2 ±0.31 .1 ±0.2
ApoB/ApoA1 ratio 0.65 ±0.20 .72 ±0.20 .80 ±0.20 .84 ±0.20 .89 ± 0.2
Systolic blood pressure (mm Hg)∗ 124 ±13 136 ±16 142 ±18 150 ±18 159 ± 18
Diastolic blood pressure (mm Hg)∗ 78 ±78 4 ±88 8 ±99 1 ±99 6 ± 9
Fibrinogen (g/L) 2.8 ±0.82 .9 ±0.83 .0 ±0.73 .0 ±0.73 .2 ±0.7
γ-Glutamyltransferase (μkat/L) 0.59 ±0.70 .64 ±0.70 .74 ±0.90 .9 ±0.91 .13 ± 1.1
Data are Mean ± SD. BP: blood pressure. ∗Risk factors included in the cardiometabolic risk score.
except to LDL cholesterol for waist girth, WHR, and BMI in
men(Table3).SADwastheonlysigniﬁcantpredictorofLDL
cholesterol, although the correlation was weak (Table 3).
Among the men, 20.4% were at elevated cardiometabolic
risk score, and among the women 22.4% were deﬁned
as having elevated cardiometabolic risk. These ﬁgures are
in accordance with those reported for this population
concerning prevalence of the metabolic syndrome [22].
SAD was more strongly correlated to most risk factors
as compared with other anthropometric measures in men
whereas in women SAD was not consistently better than
other anthropometric measures (Table 3). SAD showed the
strongest correlation with the cardiometabolic risk score
among men; whereas it was not a better correlate than
other anthropometric measures in women. The stronger
correlation between SAD and the cardiometabolic risk score
was statistically signiﬁcantly diﬀerent compared with all
other anthropometric measures in men (all P<. 5),
but was only signiﬁcantly diﬀerent from BMI in women
(Table 3).
In men, SAD showed the highest area under the ROC
curve which was statistically signiﬁcant compared with the
othermeasuresexceptBMI(P = .003,P<. 0001,andP = .09
for comparison with waist girth, WHR, and BMI, resp.), and
in women SAD showed together with waist girth the highest
area under the ROC curve (P = .9, P = .3, and P<. 001 for
comparison between SAD and waist girth, WHR, and BMI,
resp.) (Table 4).4 Journal of Obesity
Table 3: Correlation coeﬃcients between anthropometric and cardiometabolic variables.
SAD Waist WHR BMI SAD Waist WHR BMI
Men (n = 1936) Women (n = 2096)
Sagittal abdominal diameter (SAD) — 0.88 0.70 0.85 — 0.89 0.58 0.85
Cardiometabolic risk score 0.56∗ 0.53 0.53 0.49 0.50 0.51 0.44 0.51
Glucose 0.26 0.24 0.23 0.23 0.42 0.30 0.27 0.27
Insulin 0.52 0.50 0.43 0.51 0.45 0.43 0.37 0.41
Triglycerides 0.41 0.36 0.35 0.34 0.38 0.40 0.43 0.31
LDL cholesterol 0.05 0.02 0.01 0.02 0.12 0.11 0.12 0.09
HDL cholesterol −0.32 −0.32 −0.28 −0.31 −0.29 −0.37 −0.35 −0.32
apoB/apoA-1 0.26 0.24 0.21 0.23 0.29 0.31 0.32 0.25
Systolic blood pressure 0.27 0.24 0.24 0.23 0.21 0.21 0.21 0.18
Diastolic blood pressure 0.29 0.26 0.25 0.25 0.21 0.20 0.20 0.17
Fibrinogen 0.24 0.23 0.26 0.16 0.40 0.40 0.30 0.38
γ-Glutamyltransferase 0.32 0.29 0.30 0.26 0.29 0.29 0.29 0.24
Data are Pearson’s correlation coeﬃcients. WHR: waist-to-hip ratio. All correlations were signiﬁcant (P<. 05) except that for waist girth, BMI, and WHR
withLDLcholesterol inmen. ∗Thecorrelation betweenSAD andthecardiometabolicriskscore was statisticallysigniﬁcantlydiﬀerent compared withall other
anthropometric measures in men (all P<. 05), but was only signiﬁcantly diﬀerent from BMI in women.
Table 4: Area under the ROC curve for diﬀerent anthropometric measures for identifying individuals at elevated cardiometabolic risk.
Men (n = 1936)
AUC under ROC
(95% CI)
Women (n = 2096)
AUC under ROC
(95% CI)
SAD (cm) 0.80 (0.77;0.82) 0.77 (0.75;0.80)
Waist girth (cm) 0.78 (0.75;0.80) 0.77 (0.75;0.80)
Waist-to-hip ratio 0.74 (0.71;0.77) 0.76 (0.74;0.79)
BMI (kg/m2) 0.78 (0.76;0.81) 0.74 (0.72;0.77)
SAD: Sagittal abdominal diameter, CI: conﬁdence interval, BMI: body mass index.
The optimal (95% CI) SAD cutoﬀ for an elevated
calculated cardiometabolic risk score for men was 22.2 (21.6
to 22.8) and for women 20.1 (19.4 to 20.8) (Table 5). The
optimal cutoﬀs for waist girth, WHR, and BMI are shown in
Table 5.
To further validate these results, we also assessed optimal
cutoﬀs for SAD using the more established Framingham
risk score. The present SAD cutoﬀ of 22cm for men
was unchanged if replacing the cardiometabolic risk score
with Framingham risk score. In women the cutoﬀ was
21cm if using the Framingham risk score instead of the
cardiometabolic risk score.
The highest quintile of Framingham risk score started at
14riskpointsformen,andat17riskpointsforwomenwhich
corresponded to a 2% and 5% 10-year risk of cardiovascular
disease, respectively. In this population, a SAD of 22cm
corresponded to 20% risk in men, and a SAD of 21cm
corresponded to a 14% risk in women.
4. Discussion
The optimal cutoﬀs for identifying subjects with an elevated
cardiometabolic risk score were ∼22cm in men and ∼20cm
in women. These ﬁgures corresponded to a BMI ∼28 in both
sexes. This is the ﬁrst study using ROC curves to identify
cutoﬀsforSADinalargepopulation-basedsample.Basedon
a Canadian population in 81 men and 70 women, a SAD >
25cmwassuggestedtobeassociatedwithmultiplemetabolic
disorders [5]. Since the sample size of that study was small
it may be unwise to compare that study with ours where the
cutoﬀswherelower.Notably,thepresentSADcutoﬀof22cm
for men was unchanged if replacing the cardiometabolic
risk score with the Framingham risk score, a ﬁnding that
strengthen the validity of this cutoﬀ. In women the cutoﬀ
was however 1cm higher if using the Framingham risk score
instead of the cardiometabolic risk score.
In men, SAD was signiﬁcantly more closely correlated
with the cardiometabolic risk score versus all other
anthropometric measures and also showed slightly stronger
correlations with most individual risk factors. In women,
SAD was an equally good predictor for an elevated
cardiometabolic risk score as waist girth. If one should use
only one anthropometric measure, SAD thus may be a good
choice to capture elevated cardiometabolic risk. The stronger
capacity of SAD to predict cardiometabolic risk in men may
be explained by the higher visceral fat content in menJournal of Obesity 5
Table 5: Cutoﬀsf o rd i ﬀerent anthropometric measures in determining an elevated cardiometabolic risk score in men and women.
Men (n = 1936)
Mean (95% CI)
Women (n = 2096)
Mean (95% CI)
Sagittal abdominal diameter (cm) 22.2 (21.6 to 22.8) 20.1 (19.4 to 20.8)
Waist girth (cm) 100 (96.9 to 101) 88.4 (86.7 to 90)
Waist-to-hip ratio 0.97 (0.95 to 0.99) 0.82 (0.81 to 0.84)
BMI (kg/m2) 27.9 (26.8 to 29) 27.6 (27 to 28.3)
CI: conﬁdence interval, BMI: body mass index.
versus women at a given BMI. This is relevant since visceral
adiposity may confer a higher cardiometabolic risk than
otherfatdepots,althoughthishasbeendebated[34].Indeed,
SAD seems particularly good in capturing visceral fat (which
during the supine measurement does not “ﬂoat out” side-
ways, as would more be the case for subcutaneous fat) [15,
35]. Also, the cardiometabolic risk score was lower in women
(10 versus 14) providing a higher number of men at risk,
whichcouldcontributetogenderdiﬀerencesobservedinthis
study.
In line with previous data on men, but also to some
extent in women, SAD was more closely related to hyper-
lipidemia [7] and cardiovascular risk [7–9, 36, 37] than
BMI, waist girth, and WHR. Recent data also showed that
SAD was the best correlate to hypertension [7, 36]a n d
plasminogen activating inhibitor-1 [7]. Furthermore, in the
Swedish Obese Subjects study the change in SAD was most
closely related to the change of metabolic disorders [38].
We have also shown that SAD was a signiﬁcantly better
predictor of insulin resistance than waist girth in men,
even independently of BMI and waist girth [17]. Thus,
SAD may carry unique information beyond that of other
anthropometric measures. Similarly, SAD was the strongest
predictor of insulin resistance and CRP levels in healthy
women [18]. A recent study in elderly 389 men and 437
women (aged 56–83 years) did however not ﬁnd that
SAD was superior to waist with regard associations with
components of the metabolic syndrome [39]. The latter
inconsistency might be due to older age groups studied,
ethnic, sex, phenotype, or methodological diﬀerences.
One possible explanation for a somewhat better predic-
tive capacity of SAD is the higher measurement reliability
of SAD compared with waist girth [23, 40]. SAD may
also be the only measure with high reliability in both lean
and obese subjects [23]. Again, SAD may more closely
reﬂect visceral adiposity [14–16, 41] and thereby better
capture cardiometabolic risk [1]. However, it should be
noted that SAD also is a valid measure of total abdominal fat
[16].
It has been shown that a large waist is a useful tool to
detect metabolic disorders [5, 19, 20, 42]. These studies did
however not compare the predictive capacity with SAD. In
one study SAD and waist girth were equally good markers
of various metabolic disorders [5]. The present results in a
largepopulationdosuggestthatinmenSADismorestrongly
associated with individual cardiometabolic risk factors. With
regard to mortality, available studies indicate that SAD is a
strong predictor of mortality independently of BMI [10–13],
especially in younger adults [11, 13]. However, these studies
did not include waist girth or the waist-hip ratio, and only
one study included women which showed that SAD was a
stronger predictor of mortality than BMI also in women
[13]. That study also showed that SAD was good predictor
in several ethnic groups.
It has sometimes been argued that waist girth is more
practical to measure than SAD. The diﬀerence is however
negligible. Our results support the use of SAD as a valuable
screening tool in research since it is a simple, reliable, and
cheap marker to identify men at elevated cardiometabolic
risk.
There are limitations of this study. This is a cross-
sectional study and further prospective analyses will be
needed to verify SAD as a predictor of mortality. In addition,
thecardiometabolicriskscoreusedhavenotbeenestablished
as a determinant of cardiovascular events and mortality. It
should howeverbe noted thatcutoﬀsfor waist circumference
used in current clinical guidelines worldwide are based on
cross-sectional data as well [19]. Another relevant limitation
is the arbitrary deﬁnition of an elevated cardiometabolic risk
score, but similar results were obtained if the Framingham
risk score was used thus supporting the data. Strengths
of the study include the population-based, representative
sample of men and women of the same age (age 60). For
the latter reason confounding inﬂuences of age are avoided.
On the other hand, the generalizability to younger age
groups decreases. Caucasians comprised the majority of the
population but several ethnicities were represented in this
study; that is, 19% was of non-Swedish origin [43]. Notably,
SAD seems to be useful in various ethnic groups [13, 44]a n d
in a US population, SAD (measured in standing) predicted
coronary heart disease across racial groups [13].
5. Conclusion
TheoptimalcutoﬀsforSADwere>22cminmenand>20cm
in women. In line with the previous studies, SAD was the
bestmarkerofanelevatedcardiometabolicriskscoreinmen,
and at least as good as other anthropometric measures in
women. Thus, SAD may be a good alternative to waist girth
as a simple screening tool in research aiming at recruiting
subjects at elevated cardiometabolic risk, especially men.
Further evaluation of SAD is warranted in younger age
groups.6 Journal of Obesity
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